Observational study on hypertrophic cardiomyopathy in Chinese patients
The Chinese Hypertrophic Cardiomyopathy Study(CHCS)
This study is trying to understand hypertrophic cardiomyopathy in Chinese patients by collecting health information and samples to see how genetics and other factors play a role in the condition and its risks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Sex | All |
| Sponsor | China National Center for Cardiovascular Diseases Government |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT02696135 on ClinicalTrials.gov |
What this trial studies
This study focuses on hypertrophic cardiomyopathy (HCM), a common inherited cardiac condition, by recruiting patients to collect comprehensive clinical data and biological specimens. It aims to explore the genetic and molecular underpinnings of HCM through multi-omics screening, which includes genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Additionally, the study will evaluate the effectiveness of existing sudden cardiac death risk stratification guidelines in the Chinese population and identify novel risk factors and predictive models tailored for these patients.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with hypertrophic cardiomyopathy characterized by significant left ventricle wall thickness.
Not a fit: Patients with other cardiac or systemic diseases that cause similar cardiac hypertrophy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification and personalized treatment strategies for patients with hypertrophic cardiomyopathy.
How similar studies have performed: While studies on hypertrophic cardiomyopathy exist, this approach utilizing multi-omics and focusing on the Chinese population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: Patients with HCM diagnosed by observation of unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM. Exclusion criteria: Individuals with other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.
Where this trial is running
Beijing, Beijing Municipality
- Fuwai hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Song Lei, MD.&ph.D — Chinese Academy of Medical Sciences, Fuwai Hospital
- Study coordinator: Song Lei, MD.&ph.D
- Email: clinicalfw@163.com
- Phone: 86-13810532620
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.